561 Targeting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy

Or-Yam Revach; Angelina Cicerchia; Moshe Sade-Feldman; Seth Anderson; Boryana Petrova; Ofir Shorer; Lloyd Bod; Arnav Mehta; Giulia Cattaneo; Payal Tiwari; Tatyana Sharova; Hongyan Xie; William Michaud; Martin Rasmussen; Jacy Fang; Soldano Ferrone; Keith Flaherty; Genevieve M Boland; Debattama R Sen; Keren Yizhak; Naama Kanarek; Robert T Manguso; Nir Hacohen; Russell Jenkins

doi:10.1136/jitc-2023-SITC2023.0561

Article info

PDF

Regular and Young Investigator Award Abstracts

Checkpoint Blockade Therapy

561 Targeting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy

Authors

Or-Yam Revach Massachusetts General Hospital, Cambridge, MA, USA PubMed articles Google scholar articles
Angelina Cicerchia Mass General Hospital Cancer Center, Massachusetts General Hospital Boston, MA, USA PubMed articles Google scholar articles
Moshe Sade-Feldman Mass General Hospital Cancer Center, Massachusetts General Hospital Boston, MA, USA Broad Institute of MIT and Harvard, Cambridge, MA, USA PubMed articles Google scholar articles
Seth Anderson Broad Institute of MIT and Harvard, Cambridge, MA, USA PubMed articles Google scholar articles
Boryana Petrova Department of Pathology, Boston Children’s Hospital, Boston MA, Boston, MA, USA PubMed articles Google scholar articles
Ofir Shorer The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel, Israel PubMed articles Google scholar articles
Lloyd Bod Mass General Hospital Cancer Center, Massachusetts General Hospital Boston, MA, USA PubMed articles Google scholar articles
Arnav Mehta Broad Institute of MIT and Harvard, Cambridge, MA, USA Mass General Cancer Center, Harvard Medical School Hospital, Charlestown, MA, USA Massachusetts General Hospital, Boston, MA, USA PubMed articles Google scholar articles
Giulia Cattaneo Massachusetts General Hospital, Boston, MA, USA PubMed articles Google scholar articles
Payal Tiwari Broad Institute of MIT and Harvard, Cambridge, MA, USA PubMed articles Google scholar articles
Tatyana Sharova Massachusetts General Hospital, Boston, MA, USA PubMed articles Google scholar articles
Hongyan Xie Massachusetts General Hospital, Boston, MA, USA PubMed articles Google scholar articles
William Michaud Massachusetts General Hospital, Boston, MA, USA PubMed articles Google scholar articles
Martin Rasmussen Mass General Hospital Cancer Center, Massachusetts General Hospital Boston, MA, USA PubMed articles Google scholar articles
Jacy Fang Mass General Hospital Cancer Center, Massachusetts General Hospital Boston, MA, USA Broad Institute of MIT and Harvard, Cambridge, MA, USA PubMed articles Google scholar articles
Soldano Ferrone Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA PubMed articles Google scholar articles
Keith Flaherty Massachusetts General Hospital, Boston, MA, USA PubMed articles Google scholar articles
Genevieve M Boland Massachusetts General Hospital, Boston, MA, USA PubMed articles Google scholar articles
Debattama R Sen Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA PubMed articles Google scholar articles
Keren Yizhak Technion Israel Institute of Technology, Haifa, Israel PubMed articles Google scholar articles
Naama Kanarek Department of Pathology, Boston Children’s Hospital, Boston MA, Boston, MA, USA PubMed articles Google scholar articles
Robert T Manguso Broad Institute of MIT and Harvard, Cambridge, MA, USA PubMed articles Google scholar articles
Nir Hacohen Broad Institute of MIT and Harvard, Cambridge, MA, USA Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA PubMed articles Google scholar articles
Russell Jenkins Mass General Hospital Cancer Center, Massachusetts General Hospital Boston, MA, USA PubMed articles Google scholar articles

Citation

Revach O, Cicerchia A, Sade-Feldman M, et al

561 Targeting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy

Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0561

Online issue publication

November 02, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password